Zacks Research Brokers Raise Earnings Estimates for FMS

Fresenius Medical Care AG (NYSE:FMS) – Equities research analysts at Zacks Research increased their Q4 2026 earnings estimates for shares of Fresenius Medical Care in a report released on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share.

A number of other brokerages also recently weighed in on FMS. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Friday. They set a “strong-buy” rating for the company. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Truist Financial boosted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $24.30.

Fresenius Medical Care Stock Up 1.0 %

Shares of Fresenius Medical Care stock opened at $22.38 on Thursday. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The company has a 50-day moving average of $22.21 and a 200 day moving average of $20.64. The firm has a market cap of $13.13 billion, a price-to-earnings ratio of 18.50, a PEG ratio of 0.96 and a beta of 0.93.

Hedge Funds Weigh In On Fresenius Medical Care

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning increased its holdings in shares of Fresenius Medical Care by 18.9% in the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after purchasing an additional 6,373 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Fresenius Medical Care during the third quarter valued at $237,000. Wulff Hansen & CO. increased its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after buying an additional 325,439 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Fresenius Medical Care by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after buying an additional 2,233 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares during the period. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.